BLTE - Belite Bio Inc (BLTE) Q4 2023 Earnings Call Transcript
2024-03-12 19:53:07 ET
Belite Bio, Inc (BLTE)
Q4 2023 Results Conference Call
March 12, 2024 04:30 PM ET
Company Participants
Tom Lin - Chiarman and Chief Executive Officer
Nathan Mata - Chief Scientific Officer
Hao-Yuan Chuang - Chief Financial Officer
Conference Call Participants
Jennifer Kim - Cantor
Yi Chen - H.C. Wainwright
Bruce Jackson - Benchmark
Presentation
Operator
Hello, and thank you for joining us to discuss Belite Bio’s Fourth Quarter and Full-Year 2023 Financial Results. Joining the call are Dr. Tom Lin, Chairman and CEO of Belite Bio; Dr. Nathan Mata, Chief Scientific Officer; and Hao-Yuan Chuang, Chief Financial Officer.
Before we begin, let me point out that we will be making forward-looking statements that are based on current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. [Operator Instructions]
Now I'll turn the call over to Dr. Lin.
Tom Lin
Thank you. Thank you, everyone, for joining our reporting for 2023 and for this quarter. I'm Tom Lin, CEO of Belite Bio. Joining me is our CFO, Dr. Nathan Mata and CFO, Hao-Yuan.
I'd like to start off by giving an overview. So Tinlarebant is a novel once-a-day oral tablet designed to bind to serum retinal binding protein or RBP4 as a means to specifically reduce retinol delivery to the eye. This approach is intended to slow or stop the formation of the toxic retinol derived by products, which are generated in the visual cycle and are implicated in progression of Stargardt disease and Geographic Atrophy....
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript